In 2023, Swissmedic, the Swiss Agency for Therapeutic Products, authorised 41 medicinal products with new active substances for the Swiss market.
The overview shows the indications and the type and duration of the authorisation procedures. Swissmedic is also participating in two benchmarking studies to compare the authorisation times with those of the leading partner authorities. The results of these studies will be published during the course of 2024.
The following overview shows which procedures the applicants used, how long the authorisation processes lasted, and for which indications the medicines were authorised.